Protease-activated receptor-2 (PAR-2) is present in the rat hippocampus and is associated with neurodegeneration

被引:0
|
作者
SmithSwintosky, VL
CheoIsaacs, CT
DAndrea, MR
Santulli, RJ
Darrow, AL
AndradeGordon, P
机构
关键词
fura; 2; immunocytochemistry; reverse transcriptase polymerase chain reaction; neuronal survival;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protease-activated receptor-2 (PAR-2) is a seven-transmembrane G protein-coupled receptor that possesses a structure and activation mechanism similar to those of the thrombin receptor. It is activated by low concentrations of trypsin (300 pM) and a synthetic hexapeptide [sequence of serine, leucine, isoleucine, glycine, arginine, leucine (SLIGRL), the rodent PAR-2 ''tethered ligand''] representing the first six amino acids following the putative PAR-2 cleavage site. Previous studies have indicated that alpha-thrombin and SFLLRN (synthetic hexapeptide sequence of serine, phenylalanine, leucine, leucine, arginine, asparagine; the human thrombin receptor ''tethered ligand'') induce neurite retraction and neurotoxicity. Because of the strong similarities between thrombin receptor and PAR-2, we have proposed that PAR-2 may also participate in neurodegeneration. In the present study, we used reverse transcriptase polymerase chain reaction and immunocytochemistry to provide the first evidence that PAR-2 is present in the rat hippocampus. Moreover, we found SLIGRL to be toxic to hippocampal neurons in a concentration-dependent manner (greater than or equal to 100 mu M). Calcium signaling studies were performed to aid in determining the mechanism by which PAR-2 activation is neurotoxic.
引用
收藏
页码:1890 / 1896
页数:7
相关论文
共 50 条
  • [1] PROTEASE-ACTIVATED RECEPTOR-2 (PAR-2) IN THE PATHOGENESIS OF OSTEOARTHRITIS
    Ferrell, William R.
    Kelso, Elizabeth B.
    Lockhart, John C.
    Burns, Elizabeth
    Plevin, Robin
    McInnes, Iain B.
    RHEUMATOLOGY, 2011, 50 : 90 - 90
  • [2] Modulation of serum IgE by protease-activated receptor-2 (PAR-2).
    Davis, M
    Sigounas, A
    Shibata, Y
    Metzger, WJ
    Henriksen, RA
    FASEB JOURNAL, 1999, 13 (07): : A1472 - A1472
  • [3] Protease-activated receptor-2 (PAR-2) as a potential therapeutic target
    Kanke, T
    Takizawa, T
    Kabeya, M
    Kawabata, A
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 64P - 64P
  • [4] Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation
    Sanchez-Hernandez, Pedro Ernesto
    Ramirez-Duenas, Maria Guadalupe
    Albarran-Somoza, Benibelks
    Garcia-Iglesias, Trinidad
    del Toro-Arreola, Alicia
    Franco-Topete, Ramon
    Daneri-Navarro, Adrian
    GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 19 - 26
  • [5] Protease-activated receptor-2 (PAR-2): a potential new target in arthritis
    Ferrell, William R.
    Lockhart, John C.
    Plevin, Robin
    DRUGS OF THE FUTURE, 2008, 33 (03) : 241 - 248
  • [6] Activation of protease-activated receptor-2 (PAR-2) triggers mucin secretion in the rat sublingual gland
    Kawabata, A
    Morimoto, N
    Nishikawa, H
    Kuroda, R
    Oda, Y
    Kakehi, K
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 270 (01) : 298 - 302
  • [7] Activation of protease-activated receptor-2 (PAR-2) induces cardioprotection in anaesthetised mice
    Lim, SY
    Kane, KA
    Kennedy, S
    Wainwright, CL
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2005, 38 (05) : 858 - 858
  • [8] Rectal sensitivity and protease-activated receptor-2 (PAR-2) levels in ulcerative colitis
    Galeazzi, F
    Lanaro, D
    Brun, P
    Ditadi, F
    D'Odorico, A
    Palu, G
    D'Inca, R
    Castagliuolo, I
    Sturniolo, GC
    GASTROENTEROLOGY, 2003, 124 (04) : A74 - A74
  • [9] Protease-activated receptor-2 (PAR-2) expression in oral squamous cell carcinoma
    Wills, SM
    Hou, L
    Cruchley, AT
    Macey, MG
    Howells, GL
    JOURNAL OF DENTAL RESEARCH, 1998, 77 : 880 - 880
  • [10] Protease-activated receptor-2 (PAR-2) in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion
    Kawao, N
    Sakaguchi, Y
    Tagome, A
    Kuroda, R
    Nishida, S
    Irimajiri, K
    Nishikawa, H
    Kawai, K
    Hollenberg, MD
    Kawabata, A
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (05) : 1292 - 1296